Provectus Biopharmaceuticals to Present at Sidoti’s Fall 2016 Emerging Growth Conference, November 1,
2016
Presentation Scheduled for 9:15 am, New York Marriott Marquis; to be Webcast, Available on Company
Website
Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the
"Company”), today announced that it will present at Sidoti and Company’s Fall 2016 Emerging Growth Conference.
The presentation is scheduled for 9:15 am on Tuesday, November 1, 2016. The conference will be held at the New York Marriott
Marquis hotel.
Provectus will post the presentation on its Company website and will webcast the presentation, accessible via this link:
http://wsw.com/webcast/sidotico2/pvct
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer.
Provectus’ investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. The
Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has
completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit
the Company's website at www.provectusbio.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws.
These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's
current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate,"
"believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms.
Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking
statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A
of our Annual Report on Form 10-K for the year ended December 31, 2015) and the following:
- our determination, based on guidance from the FDA, whether to proceed with or without a partner with
the fully enrolled phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma and the costs associated with such a trial
if it is necessary to complete (versus interim data alone);
- our determination whether to license PV-10, our investigational drug product for melanoma and other
solid tumors such as cancers of the liver, if such licensure is appropriate considering the timing and structure of such a
license, or to commercialize PV-10 on our own to treat melanoma and other solid tumors such as cancers of the liver;
- our ability to license PH-10, our investigational drug product for dermatology, on the basis of our
phase 2 atopic dermatitis and psoriasis results, which are in the process of being further developed in conjunction with
mechanism of action studies;
- our ability to raise additional capital if we determine to commercialize PV-10 and/or PH-10 on our
own, although our expectation is to be acquired by a prospective pharmaceutical or biotech concern prior to commercialization;
and
- our ability to raise capital through our proposed rights offering.
Provectus Biopharmaceuticals, Inc.
Peter R. Culpepper, 866-594-5999 #30
Interim CEO, COO
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, 212-564-4700
DM, SVP – Investor Relations
or
Allison + Partners
Todd Aydelotte, 646-428-0644
Managing Director – Media Relations
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027005204/en/